CAR-modified T-cell therapy for cancer: an updated review

References

• Ahmed M, Cheung N-KV. 2013. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 588:288–297.
   PubMed Web of Science ®Google Scholar
• Beecham EJ, Ma Q, Ripley R, Junghans RP. 2000. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J Immunother. 23:631–642.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Rössig C, Calonge MJ, Huls MH, Wagner H-J, Massague J, et al. 2002. Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity. Blood. 99:3179–3187.
   PubMed Web of Science ®Google Scholar
• Borkner L, Kaiser A, Van De Kasteele W, Andreesen R, Mackensen A, Haanen JB, et al. 2010. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother. 59:1173–1183.
   PubMed Web of Science ®Google Scholar
• Brayer JB, Pinilla-Ibarz J. 2013. Developing strategies in the immunotherapy of leukemias. Cancer Control. 20:49–59.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 118:4817–4828.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. 2007. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 13:5426–5435.
   PubMed Web of Science ®Google Scholar
• Bretscher PA. 1999. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA. 96: 185–190.
   PubMed Web of Science ®Google Scholar
• Brocker T. 2000. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 96:1999–2001.
   PubMed Web of Science ®Google Scholar
• Burks A, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. 2013. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 131:1288–1296.e3.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. 2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA. 106:3360–3365.
   PubMed Web of Science ®Google Scholar
• Chambers CA, Allison JP. 1997. Co-stimulation in T cell responses. Curr Opin Immunol. 9:396–404.
   PubMed Web of Science ®Google Scholar
• Chang L, Chang W, Mcnamara G, Aguilar B, Ostberg J, Jensen M. 2007. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning. Cytotherapy. 9:771–784.
   PubMed Web of Science ®Google Scholar
• Chekmasova AA, Rao TD, Nikhamin Y, Park KJ, Levine DA, Spriggs DR, Brentjens RJ. 2010. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 16:3594–3606.
   PubMed Web of Science ®Google Scholar
• Chen L. 2004. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nat Rev Immunol. 4:336–347.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. 2013. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 13:227–242.
   PubMed Web of Science ®Google Scholar
• Chmielewski M, Kopecky C, Hombach AA, Abken H. 2011. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71:5697–5706.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson D, He S, Hughes T, Zhang J, et al. 2014. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 28:917–927.
   PubMed Web of Science ®Google Scholar
• Croft M. 2005. The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM–BTLA. Trends Immunol. 26:292–294.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949.
   PubMed Web of Science ®Google Scholar
• Darcy PK, Kershaw MH, Trapani JA, Smyth MJ. 1998. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol. 28:1663–1672.
   Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. 2009. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 113:6392–6402.
   PubMed Web of Science ®Google Scholar
• Durrant DM, Metzger DW. 2010. IL-12 can alleviate Th17-mediated allergic lung inflammation through induction of pulmonary IL-10 expression. Mucosal Immunol. 3:301–311.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 90:720–724.
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Traverso P, Parodi A, Kalli F, Zanetti M, Filaci G. 2013. Generation of more effective cancer vaccines. Hum Vaccin Immunother. 9:2543–2547.
   PubMed Web of Science ®Google Scholar
• Finney HM, Akbar AN, Lawson AD. 2004. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol. 172:104–113.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells. J Exp Med. 202:907–912.
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. 2014. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells. Blood. 123:2343–2354.
   PubMed Web of Science ®Google Scholar
• Goldberger O, Volovitz I, Machlenkin A, Vadai E, Tzehoval E, Eisenbach L. 2008. Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res. 68:3450–3457.
   PubMed Web of Science ®Google Scholar
• Gong MC, Latouche J-B, Krause A, Heston WD, Bander NH, Sadelain M. 1999. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1:123.
   PubMedGoogle Scholar
• Gorelik L, Flavell RA. 2002. Transforming growth factor-β in T-cell biology. Nat Rev Immunol. 2:46–53.
   PubMed Web of Science ®Google Scholar
• Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. 2013. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2:e105.
   PubMedGoogle Scholar
• Gross G, Waks T, Eshhar Z. 1989. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 86:10024–10028.
   PubMed Web of Science ®Google Scholar
• Grossi JA, Raulet DH, Allison JP. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 356:607–609.
   PubMed Web of Science ®Google Scholar
• Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, Darcy PK. 2001. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FcεRI-γ. J Immunol. 166:182–187.
   PubMed Web of Science ®Google Scholar
• Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, et al. 2002. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol. 169:5780–5786.
   PubMed Web of Science ®Google Scholar
• Heuser C, Hombach A, Lösch C, Manista K, Abken H. 2003. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther. 10:1408–1419.
   PubMed Web of Science ®Google Scholar
• Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. 2009. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 32:169.
   PubMed Web of Science ®Google Scholar
• Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Kruis W, et al. 1997. T cell targeting of TAG72 + tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology. 113:1163–1170.
   PubMed Web of Science ®Google Scholar
• Hombach A, Schneider C, Sent D, Koch D, Willemsen RA, Diehl V, et al. 2000. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer. 88:115–120.
   PubMed Web of Science ®Google Scholar
• Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, et al. 2001a. T-Cell activation by recombinant receptors cd28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res. 61:1976–1982.
   PubMed Web of Science ®Google Scholar
• Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. 2001b. Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol. 167:6123–6131.
   PubMed Web of Science ®Google Scholar
• Hosseini M, Haji-Fatahaliha M, Jadidi-Niaragh F, Majidi J, Yousefi M. 2015. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif Cells Nanomed Biotechnol. 1–11.
   Google Scholar
• Hu Z, Xia J, Wargo J, Yang Y-G. 2013. Generation of human T cells expressing only the engineered tumor antigen specific TCR in humanized mice for preclinical research and anticancer therapy (P4364). J Immunol. 190:177.15.
   Web of Science ®Google Scholar
• Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. 2013. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 19:3153–3164.
   PubMed Web of Science ®Google Scholar
• Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. 2010. The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1- specific chimeric antigen receptor. Blood. 116:4532–4541.
   PubMed Web of Science ®Google Scholar
• Hwu P, Shafer G, Treisman J, Schindler D, Gross G, Cowherd R, et al. 1993. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 178:361–366.
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Ritz J. 2011. Time to put the CAR-T before the horse. Blood. 118:4761–4762.
   PubMed Web of Science ®Google Scholar
• Jameson SC, Masopust D. 2009. Diversity in T cell memory: an embarrassment of riches. Immunity. 31:859–871.
   PubMed Web of Science ®Google Scholar
• Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ. 2013. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PloS one. 8:e57838.
   PubMed Web of Science ®Google Scholar
• Jensen MC, Popplewell L, Cooper LJ, Digiusto D, Kalos M, Ostberg JR, Forman SJ. 2010. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19- specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 16:1245–1256.
   PubMed Web of Science ®Google Scholar
• June CH. 2007. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 117:1466–1476.
   PubMed Web of Science ®Google Scholar
• Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. 2004. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64:9160–9166.
   PubMed Web of Science ®Google Scholar
• Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. 2012. The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br J Cancer. 106:1123–1133.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 3:95ra73.
   Web of Science ®Google Scholar
• Katz SC, Burga RA, Mccormack E, Wang LJ, Mooring JW, Point G, et al. 2015. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases. Clin Cancer Res. 1421.2014.
   Google Scholar
• Kazemi T, Younesi V, Jadidi-Niaragh F, Yousefi M. 2015. Immunotherapeutic approaches for cancer therapy: an updated review. Artif Cells Nanomed Biotechnol. 1–11.
   Google Scholar
• Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 121:4746.
   PubMed Web of Science ®Google Scholar
• Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al. 2010. Tumor-specific CD8 + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70:6725–6734.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, et al. 2002. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 13:1971–1980.
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 12:6106–6115.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells. Blood. 119:2709–2720.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. 2014. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 33:540–549.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. 2009. Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor. J Immunother. 32:689.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler- Stevenson M, Feldman SA, et al. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 116: 4099–4102.
   PubMed Web of Science ®Google Scholar
• Koehler H, Kofler D, Hombach A, Abken H. 2007. CD28 Costimulation Overcomes Transforming Growth Factor-β–Mediated Repression of Proliferation of Redirected Human CD4+ and CD8+ T Cells in an Antitumor Cell Attack. Cancer Res. 67:2265–2273.
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. 2015. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 4:e994446.
   PubMed Web of Science ®Google Scholar
• Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. 2006. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66:10995–11004.
   PubMed Web of Science ®Google Scholar
• Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, et al. 2012. TIL therapy broadens the tumor-reactive CD8 + T cell compartment in melanoma patients. Oncoimmunology. 1:409–418.
   PubMed Web of Science ®Google Scholar
• Ladygina N, Gottipati S, Ngo K, Castro G, Ma JY, Banie H, et al. 2013. PI3Kγ kinase activity is required for optimal T-cell activation and differentiation. Eur J Immunol. 43:3183–3196.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Gratama JW, Warnaar SO, Stoter G, Bolhuis RL. 1995. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer. 60:450–457.
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 24:e20–e22.
   PubMedGoogle Scholar
• Lamers CH, Willemsen R, Van Elzakker P, Van Steenbergen-Langeveld S, Broertjes M, Oosterwijk-Wakka J, et al. 2011. Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells. Blood. 117:72–82.
   PubMed Web of Science ®Google Scholar
• Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. 2011. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71:2871–2881.
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Walunas TL, Bluestone JA. 1996. CD28/B7 system of T cell costimulation. Ann Rev Immunol. 14:233–258.
   PubMed Web of Science ®Google Scholar
• Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner M. 2006. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 20:1819–1828.
   PubMed Web of Science ®Google Scholar
• Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. 2011. Antitumor activity and long-term fate of chimeric antigen receptor– positive T cells in patients with neuroblastoma. Blood. 118:6050–6056.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol. 20:70–75.
   PubMed Web of Science ®Google Scholar
• Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, et al. 1997. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 5:401–407.
   Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. 2013. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 36:133–151.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. 2010. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851.
   PubMed Web of Science ®Google Scholar
• Muniappan A, Banapour B, Lebkowski J, Talib S. 2000. Ligand- mediated cytolysis of tumor cells: use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther. 7:128–134.
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP. 2006. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol. 3:668–681.
   PubMedGoogle Scholar
• Murphy A, Westwood J, Brown L, Teng M, Moeller M, Xu Y, et al. 2007. Antitumor activity of dual-specific T cells and influenza virus. Cancer Gene Ther. 14:499–508.
   PubMed Web of Science ®Google Scholar
• Näslund TI, Gehrmann U, Qazi KR, Karlsson MC, Gabrielsson S. 2013. Dendritic cell–derived exosomes need to activate both T and B cells to induce antitumor immunity. J Immunol. 190:2712–2719.
   PubMed Web of Science ®Google Scholar
• Niederman TM, Ghogawala Z, Carter BS, Tompkins HS, Russell MM, Mulligan RC. 2002. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA. 99:7009–7014.
   PubMed Web of Science ®Google Scholar
• Pameijer C, Navanjo A, Meechoovet B, Wagner J, Aguilar B, Wright C, et al. 2007. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 14:91–97.
   PubMed Web of Science ®Google Scholar
• Parente-Pereira AC, Burnet J, Ellison D, Foster J, Davies DM, Van Der Stegen S, et al. 2011. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol. 31:710–718.
   PubMed Web of Science ®Google Scholar
• Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 15:825–833.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. 2012. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 119:4133–4141.
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. 2005. CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev. 4:526–531.
   PubMed Web of Science ®Google Scholar
• Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, et al 2003. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 63:2470–2476.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. 2011. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med. 365:725–733.
   PubMed Web of Science ®Google Scholar
• Pranchevicius M-CS, Vieira TR. 2013. Production of recombinant immunotherapeutics for anticancer treatment: The role of bioengineering. Bioengineered. 4:305–312.
   PubMed Web of Science ®Google Scholar
• Pritchard M, Wolf S, Kraybill W, Repasky EA. 2005. The anti-tumor effect of interleukin-12 is enhanced by mild (fever-range) thermal therapy. Immunol Invest. 34:361–380.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. 2008. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 14:1264–1270.
   PubMed Web of Science ®Google Scholar
• Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. 2005. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 12:933–941.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. 2007. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol. 25:267.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 173:7125–7130.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 21:233–240.
   PubMed Web of Science ®Google Scholar
• Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. 2002. Epstein-Barr virus–specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 99:2009–2016.
   PubMed Web of Science ®Google Scholar
• Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE. 2010. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther. 10:77–90.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Rivière I, Brentjens R. 2003. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 3:35–45.
   PubMed Web of Science ®Google Scholar
• Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, Punzalan B, et al. 2009. Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med. 15:338–344.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. 2011. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. J Clin Invest. 121:1822.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570.
   PubMed Web of Science ®Google Scholar
• Seliger B. 2008. Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol. 5:361–367.
   PubMed Web of Science ®Google Scholar
• Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Jamnani FR, Moghimi SM. 2013. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett. 334:237–244.
   PubMed Web of Science ®Google Scholar
• Smith-Garvin JE, Koretzky GA, Jordan MS. 2009. T cell activation. Ann Rev Immunol. 27:591–619.
   PubMed Web of Science ®Google Scholar
• Spear P, Barber A, Rynda-Apple A, Sentman CL. 2012. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol. 188:6389–6398.
   PubMed Web of Science ®Google Scholar
• Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E, et al. 2009. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA. 106:5784–5788.
   PubMed Web of Science ®Google Scholar
• Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, et al. 2010. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther. 18:2006–2017.
   PubMed Web of Science ®Google Scholar
• Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. 2012. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 18:6436–6445.
   PubMed Web of Science ®Google Scholar
• Tassev D, Cheng M, Cheung N-K. 2012. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 19:84–100.
   PubMed Web of Science ®Google Scholar
• Teng MW, Kershaw MH, Moeller M, Smyth MJ, Darcy PK. 2004. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther. 15:699–708.
   PubMed Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. 2008. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 112:2261–2271.
   PubMed Web of Science ®Google Scholar
• Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, et al. 2012. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4–1BB domains: pilot clinical trial results. Blood. 119:3940–3950.
   PubMed Web of Science ®Google Scholar
• Tomihara K, Curiel TJ, Zhang B. 2013. Optimization of immunotherapy in elderly cancer patients. Critical Reviews^™ in Oncogenesis. 18.
   PubMedGoogle Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, Mcdermott DF, et al. 2012. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Pflanz S, Kastelein RA. 2003. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 19:641–644.
   PubMed Web of Science ®Google Scholar
• Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, et al. 2012. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72:1844–1852.
   PubMed Web of Science ®Google Scholar
• Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, et al. 2006. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 108:3890–3897.
   PubMed Web of Science ®Google Scholar
• Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, et al. 2007. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 18:712–725.
   PubMed Web of Science ®Google Scholar
• Wang J, Press OW, Lindgren CG, Greenberg P, Riddell S, Qian X, et al. 2004. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8 + cytotoxic T lymphocytes. Mol Ther. 9:577–586.
   PubMed Web of Science ®Google Scholar
• Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, et al. 2005. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA. 102:19051–19056.
   PubMed Web of Science ®Google Scholar
• Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, et al. 2011. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 19:751–759.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, et al. 2009. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 183:5563–5574.
   PubMed Web of Science ®Google Scholar
• Zhong X-S, Matsushita M, Plotkin J, Riviere I, Sadelain M. 2010. Chimeric Antigen Receptors Combining 4–1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8 & plus; T Cell–mediated Tumor Eradication. Mol Ther. 18:413–420.
   PubMed Web of Science ®Google Scholar
• Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. 2007. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med. 357: 1293–1300.
   PubMed Web of Science ®Google Scholar